Pluristem Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch PSTI and buy or sell other stocks, ETFs, and their options commission-free!

About PSTI

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. 

CEO
Yaky Yanay, CPA
CEOYaky Yanay, CPA
Employees
127
Employees127
Headquarters
Haifa, Haifa
HeadquartersHaifa, Haifa
Founded
2001
Founded2001
Employees
127
Employees127

PSTI Key Statistics

Market cap
38.41M
Market cap38.41M
Price-Earnings ratio
-1.04
Price-Earnings ratio-1.04
Dividend yield
Dividend yield
Average volume
4.93K
Average volume4.93K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$7.13
52 Week high$7.13
52 Week low
$2.82
52 Week low$2.82

Stock Snapshot

Pluristem Therapeutics(PSTI) stock is priced at $3.85, giving the company a market capitalization of 38.41M. It carries a P/E multiple of -1.04.

During the trading day, Pluristem Therapeutics(PSTI) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 4.93K.

Over the past 52 weeks, Pluristem Therapeutics(PSTI) stock has traded between a high of $7.13 and a low of $2.82.

Over the past 52 weeks, Pluristem Therapeutics(PSTI) stock has traded between a high of $7.13 and a low of $2.82.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.